NCT07914582 Steatotic Liver Disease in Austria - Prospective Registry With Biobank
| NCT ID | NCT07914582 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Steatotic Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2040-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2025-07-01 with a primary completion date of 2040-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Steatotic liver disease (SLD) is the most common chronic liver disease and is associated with an increased risk of liver-related complications, cardiovascular disease, and malignancies. However, comprehensive prospective data on the clinical characteristics, disease progression, and management of patients with SLD in Austria remain limited. The SLD-AT study is a multicenter, prospective, observational registry with an associated biobank aiming to characterize patients with suspected or confirmed SLD in Austria. The registry will collect longitudinal clinical, laboratory, imaging, and treatment-related data to investigate disease progression, clinical outcomes, and the prognostic value of non-invasive tests and biomarkers. The study aims to enroll approximately 20,000 participants over a planned duration of 15 years.
Eligibility Criteria
Inclusion Criteria: * 1\. Age 18-100 years. * 2\. Suspected steatotic liver disease (SLD), defined by at least one of the following criteria: * Suspected SLD based on previous medical findings. * Evidence of hepatic steatosis assessed by, Controlled attenuation parameter (CAP), Ultrasound, Magnetic resonance imaging (MRI), or Liver histology * Suspected advanced liver fibrosis assessed by Vibration-controlled transient elastography (VCTE; ≥8 kPa), Ultrasound, Magnetic resonance elastography (MRE), or Liver histology * Elevated liver enzymes (AST, ALT, and/or GGT) within 6 months prior to enrollment. * 3\. Written informed consent to participate in the registry. Exclusion Criteria: * Withdrawal of written informed consent. * Diagnosis of any of the following active chronic liver diseases: * Chronic hepatitis B * Chronic hepatitis C * Autoimmune or cholestatic liver disease * Genetic liver disease * Current diagnosis of alcohol-associated hepatitis. * Current decompensated liver cirrhosis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07914582 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Steatotic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07914582 currently recruiting?
Yes, NCT07914582 is actively recruiting participants. Contact the research team at sld@meduniwien.ac.at for enrollment information.
Where is the NCT07914582 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT07914582 clinical trial?
NCT07914582 is sponsored by Medical University of Vienna. The trial plans to enroll 20,000 participants.